Sodium Thiosulfate in Acute Myocardial Infarction:: A Randomized Clinical Trial

Marie-Sophie Ly de Koning; Paulien van Dorp; Solmaz Assa; Gabija Pundziute-Do Prado; Michiel Voskuil; Rutger L Anthonio; Duco Veen; Tim Leiner; Anita J. Sibeijn-Kuiper; Harry van Goor; Dirk J van Veldhuisen; Peter van der Meer; Robin Nijveldt; Eric Lipsic; Pim van der Harst

doi:10.1016/j.jacbts.2023.06.001

Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Marie-Sophie Ly de Koning, Paulien van Dorp, Solmaz Assa, Gabija Pundziute-Do Prado, Michiel Voskuil, Rutger L Anthonio, Duco Veen, Tim Leiner, Anita J. Sibeijn-Kuiper, Harry van Goor, Dirk J van Veldhuisen, Peter van der Meer, Robin Nijveldt, Eric Lipsic, Pim van der Harst^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first
ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at
arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic
resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes
were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large
infarction.

Original language	English
Pages (from-to)	1285-1294
Journal	JACC: Basic to Translational Science
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/j.jacbts.2023.06.001
Publication status	Published - 2023

Keywords

clinical trial
hydrogen sulfide
ischemia-reperfusion injury
myocardial infarction
randomized controlled trial
thiosulfates

Access to Document

10.1016/j.jacbts.2023.06.001Licence: CC BY

Sodium Thiosulfate in Acute Myocardial InfarctionFinal published version, 966 KBLicence: CC BY

Cite this

de Koning, M.-S. L., van Dorp, P., Assa, S., Pundziute-Do Prado, G., Voskuil, M., Anthonio, R. L., Veen, D., Leiner, T., Sibeijn-Kuiper, A. J., van Goor, H., van Veldhuisen, D. J., van der Meer, P., Nijveldt, R., Lipsic, E., & van der Harst, P. (2023). Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial. JACC: Basic to Translational Science, 8(10), 1285-1294. https://doi.org/10.1016/j.jacbts.2023.06.001

@article{9b5bf5c0453b4096af22f6830a240139,

title = "Sodium Thiosulfate in Acute Myocardial Infarction:: A Randomized Clinical Trial",

abstract = "In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a firstST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo atarrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magneticresonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomeswere comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for largeinfarction.",

keywords = "clinical trial, hydrogen sulfide, ischemia-reperfusion injury, myocardial infarction, randomized controlled trial, thiosulfates",

author = "{de Koning}, {Marie-Sophie Ly} and {van Dorp}, Paulien and Solmaz Assa and {Pundziute-Do Prado}, Gabija and Michiel Voskuil and Anthonio, {Rutger L} and Duco Veen and Tim Leiner and Sibeijn-Kuiper, {Anita J.} and {van Goor}, Harry and {van Veldhuisen}, {Dirk J} and {van der Meer}, Peter and Robin Nijveldt and Eric Lipsic and {van der Harst}, Pim",

year = "2023",

doi = "10.1016/j.jacbts.2023.06.001",

language = "English",

volume = "8",

pages = "1285--1294",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier",

number = "10",

}

de Koning, M-SL, van Dorp, P, Assa, S, Pundziute-Do Prado, G, Voskuil, M, Anthonio, RL, Veen, D, Leiner, T, Sibeijn-Kuiper, AJ, van Goor, H, van Veldhuisen, DJ, van der Meer, P, Nijveldt, R, Lipsic, E & van der Harst, P 2023, 'Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial', JACC: Basic to Translational Science, vol. 8, no. 10, pp. 1285-1294. https://doi.org/10.1016/j.jacbts.2023.06.001

TY - JOUR

T1 - Sodium Thiosulfate in Acute Myocardial Infarction:

T2 - A Randomized Clinical Trial

AU - de Koning, Marie-Sophie Ly

AU - van Dorp, Paulien

AU - Assa, Solmaz

AU - Pundziute-Do Prado, Gabija

AU - Voskuil, Michiel

AU - Anthonio, Rutger L

AU - Veen, Duco

AU - Leiner, Tim

AU - Sibeijn-Kuiper, Anita J.

AU - van Goor, Harry

AU - van Veldhuisen, Dirk J

AU - van der Meer, Peter

AU - Nijveldt, Robin

AU - Lipsic, Eric

AU - van der Harst, Pim

PY - 2023

Y1 - 2023

N2 - In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a firstST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo atarrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magneticresonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomeswere comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for largeinfarction.

AB - In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a firstST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo atarrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magneticresonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomeswere comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for largeinfarction.

KW - clinical trial

KW - hydrogen sulfide

KW - ischemia-reperfusion injury

KW - myocardial infarction

KW - randomized controlled trial

KW - thiosulfates

U2 - 10.1016/j.jacbts.2023.06.001

DO - 10.1016/j.jacbts.2023.06.001

M3 - Article

SN - 2452-302X

VL - 8

SP - 1285

EP - 1294

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 10

ER -

Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this